Binimetinib vs Luvometinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MEK1/2 · full Non-Small Cell Lung Cancer pipeline

Binimetinib

Marketed by Pfizer and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT03915951 · Phase 2 · completed

This was a single-group, open-label study of 98 participants receiving encorafenib plus binimetinib, without randomization or a placebo or active-control arm. The primary imaging-based tumor-response endpoint was reported descriptively, so there was no controlled statistical comparison demonstrating that binimetinib improved outcomes.

Next expected readout: August 2027 · NCT05355701 (registry estimate)

No aligned efficacy figure on record for this race.

Luvometinib

Marketed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2029 · NCT07562581 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBinimetinibLuvometinib
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR74.6%bn 59NCT03915951
3 other results
—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Binimetinib
—Not reported
Luvometinib
—Not reported

OS, median

Binimetinib
—Not reported
Luvometinib
—Not reported

ORR

Binimetinib
74.6%bn 59NCT03915951
3 other results
Luvometinib
—Not reported

Duration of response, median

Binimetinib
—Not reported
Luvometinib
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Luvometinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Binimetinib: 3 of 4 rows · Luvometinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBinimetinib
Dropout rate
n/a: no completion milestonePreviously Treated
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
n/a: no completion milestoneTreatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Discontinued due to AEs
15.4%Previously Treated
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
20.3%Treatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Serious AEs
43.6%Previously Treated
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
42.4%Treatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Most frequent reported AEs
diarrhoea 51.3%
nausea 48.7%
fatigue 41%
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
nausea 62.7%
diarrhoea 49.2%
fatigue 49.2%
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Binimetinib

ORR 74.6% (n=59)
responder rate · % of participants
No placebo or comparator arm
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 3 more results
46.2% (n=39)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
62.7% (n=59)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
41% (n=39)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Disease Control 64.4% (n=59) @ 24wk
responder rate · % of participants
No placebo or comparator arm
DCR After 24 Weeks by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
41% (n=39) @ 24wk
DCR After 24 Weeks by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Time to Response 1.86 months
time to event · months
No placebo or comparator arm
TTR by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
1.74 months
TTR by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Binimetinib's landscape · Luvometinib's landscape